Trabalho realizado no Centro busca suprir demanda nacional interna, tanto de testes de toxicidade de fármacos e cosméticos como opção alternativa aos testes com animais, quanto de produção própria de curativos com células humanas, que não podem ser importados
Formulation of innovative therapeutic strategies based on viral vectors, nanoparticles, chimeric aptamers and monoclonal antibodies. This group has expertise in the production of vectors derived from retroviruses, lentiviruses, adenoviruses and adeno-associated viruses, and can also generate cell banks that produce human monoclonal antibodies, known as research cell banks (RCB)
This center uses innovative biomaterial formulations and bioprinting technologies to develop 3D cell models. It focuses on creation of in vitro models as alternatives to animal testing and on progress in advanced therapies, with emphasis on the development of biodressings
This center is dedicated to establishing gene therapy strategies using CRISPR/Cas9, base editing and prime editing to treat diseases that still do not have cures. The team has also been working to optimize encapsulation and delivery of these advanced therapy products (ATP) to develop safer and more effective treatments
This center develops mass spectrometry proteomics methods to identify and quantify proteins and peptides, including spatial, structural, single-cell and computational proteomics. The work focuses on discovery and validation of molecular signatures with diagnostic, prognostic and therapeutic potential that are aligned with precision medicine and health innovation
Develops precise computational models to understand biomacromolecular systems, accelerating the production of experimental findings
